Dr. Turang Ed Behbahani, MD, PhD

Dr. Behbahani practices at Methodist Hospital in Saint Louis Park, Minnesota, part of HealthPartners.

Dr. Behbahani's NPI, 1972846343, was assigned on April 3, 2013. Dr. Behbahani holds Minnesota license 66404.

Dr. Behbahani's primary practice is Methodist Hospital, at 6500 Excelsior Blvd, Saint Louis Park, MN 55426 in Hennepin County. The practice phone is (952) 993-5000.

Dr. Behbahani's primary practice is Methodist Hospital in Saint Louis Park, Minnesota, part of HealthPartners. Dr. Behbahani is also affiliated with Emory University Hospital. The medical group on file is Park Nicollet Clinic. Dmand AI also links Dr. Behbahani to 1 more hospital, 1 group practice or clinic, 1 hospice and 1 medical group, each named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Behbahani practices, 5 sites in all. Vendor and product names are available with a free account.

Hematology and oncology is Dr. Behbahani's primary specialty in the NPI Registry, under taxonomy code 207RH0003X. Dmand AI has Dr. Behbahani's licenses on file in 2 states: Minnesota and Georgia.

CMS data shows 36,255 Medicare services from Dr. Behbahani across 37 procedure codes in 2024, for 372 Medicare patients. Medicare paid $1,120,192 for them.

CMS counts 372 Medicare patients who saw Dr. Behbahani in 2024. The largest group is 65 to 74, with 148 patients. 64% of them have high blood pressure, and 53% have high cholesterol. 8% are also on Medicaid. Their average risk score is 2.14, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. Behbahani's median patient age at 70, with 39% women.

In 2024, Dr. Behbahani wrote 1,560 Medicare Part D claims for 215 patients. 77% of them were for generic drugs. CMS names the drug for 1,301 of them, across 32 drugs with 11 or more claims each, at $3,595,961 in total drug cost. In 2023, CMS named 1,134 claims across 36 drugs.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 99 out of 100 for Dr. Behbahani for performance year 2024, reported individually. Dr. Behbahani accepts Medicare assignment, so Medicare's approved amount is taken as full payment. CMS lists Dr. Behbahani as offering telehealth.

Dmand AI links 8 papers to Dr. Behbahani, published from 2011 to 2020. 2011 was the busiest year, with 3. The most frequent topics are Escherichia coli, Histones and Immunohistochemistry. Dr. Behbahani has published most often in BMC Urol. Dr. Behbahani's most frequent co-authors are William B. Parker, MD and Eben L. Rosenthal, MD.

CMS Open Payments shows 1 general payment to Dr. Behbahani from 1 drug or device company in 2024. Education make up the largest share, 100% of the total. Bristol-Myers Squibb Company paid the most, $16.